BAX vs. EW, RMD, IDXX, DXCM, STE, PODD, HOLX, GMED, MASI, and TFX
Should you be buying Baxter International stock or one of its competitors? The main competitors of Baxter International include Edwards Lifesciences (EW), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Insulet (PODD), Hologic (HOLX), Globus Medical (GMED), Masimo (MASI), and Teleflex (TFX). These companies are all part of the "health care equipment" industry.
Baxter International vs.
Edwards Lifesciences (NYSE:EW) and Baxter International (NYSE:BAX) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.
Baxter International has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.
In the previous week, Edwards Lifesciences had 18 more articles in the media than Baxter International. MarketBeat recorded 20 mentions for Edwards Lifesciences and 2 mentions for Baxter International. Edwards Lifesciences' average media sentiment score of 0.79 beat Baxter International's score of 0.21 indicating that Edwards Lifesciences is being referred to more favorably in the media.
Edwards Lifesciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Baxter International has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.
Edwards Lifesciences received 601 more outperform votes than Baxter International when rated by MarketBeat users. Likewise, 71.00% of users gave Edwards Lifesciences an outperform vote while only 65.62% of users gave Baxter International an outperform vote.
Edwards Lifesciences presently has a consensus price target of $78.48, indicating a potential upside of 12.19%. Baxter International has a consensus price target of $40.45, indicating a potential upside of 29.26%. Given Baxter International's higher possible upside, analysts clearly believe Baxter International is more favorable than Edwards Lifesciences.
79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 1.3% of Edwards Lifesciences shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Edwards Lifesciences has a net margin of 70.82% compared to Baxter International's net margin of 0.77%. Edwards Lifesciences' return on equity of 20.76% beat Baxter International's return on equity.
Summary
Edwards Lifesciences beats Baxter International on 13 of the 18 factors compared between the two stocks.
Get Baxter International News Delivered to You Automatically
Sign up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Baxter International Competitors List
Related Companies and Tools
This page (NYSE:BAX) was last updated on 1/21/2025 by MarketBeat.com Staff
